Changes in cell-mediated cytotoxicity during the clinical course of patients with bladder carcinoma.
The conventional cell-mediated cytotoxicity assay was modified so that more useful estimates of cell-mediated immunity to transitional cell carcimoma of the urinary tract could be obtained. With this modified assay changes in the levels of cell-mediated immunity in transitional cell carcinoma patients to transitional cell carcinoma target cells were measured during the clinical course. Initial results from a small number of patients with invasive and non-invasive tumors showed that anti-transitional cell carcinoma cell-mediated immunity increased after the tumor was removed and during administration of Bacillus Calmette-Guerin.
D001500:BCG Vaccine; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000601:surgery; D006801:Humans; D007111:Immunity, Cellular; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D009163:Mycobacterium bovis; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000601:surgery
D001500:BCG Vaccine